Clinical trial
Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of…
NCT00121849 · Access to Advanced Health Institute (AAHI), Other · Completed
Key facts
| NCT number | NCT00121849 |
|---|---|
| Title | Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite |
| Official title | A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Leish-111f + MPL-SE Vaccine in Montenegro Skin Test-Positive Healthy Adults |
| Lead sponsor | Access to Advanced Health Institute (AAHI), Other |
| Collaborators | Bill and Melinda Gates Foundation |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cutaneous Leishmaniasis |
| Intervention type | Biological |
| Interventions | Leish-111f + MPL-SE vaccine |
| Enrollment | 12 |
| Start date | Aug 1, 2005 |
| Completion | Feb 1, 2006 |
| First posted | Jul 21, 2005 |
| Last update posted | May 5, 2006 |
| Countries | Colombia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: